Accumulation of AGEs and VEGF in eyes of SDT rats

Open Diabetes Journal

Volumn 4, Issue SPEC. ISSUE 1, 2011, Pages 41-44

  Toyoda, Fumihiko ^a   Kakehashi, Akihiro ^a   Hashimoto, Kana ^a   Kinoshita, Nozomi ^a   Kanbara, Chiho ^a   Yamagami, Hiroko ^a   Tamemoto, Hiroyuki ^a   Ishikawa, San e ^a   Dobashi, Yoh ^a   Kawakami, Masanobu ^a   Kanazawa, Yasunori ^b  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Japan Diabetes Foundation   (Japan)

Author keywords

Advanced glycation end products (AGES); Diabetes; Diabetic retinopathy; Vascular endothelial growth factor (VEGF)

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; CARBOHYDRATE DERIVATIVE; GLUCOSE; PENTOSIDINE; PYRRALINE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE SEVERITY; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RAT STRAIN; RETINA NEOVASCULARIZATION; SPONTANEOUSLY DIABETIC TORII RAT;

EID: 80455125722     PISSN: None     EISSN: 18765246     Source Type: Journal    
DOI: 10.2174/1876524601104010041     Document Type: Article

References (32)

1. Hyman L. Epidemiology of eye disease in the elderly. Eye 1987; 1 (Pt 2): 330-41.
2. Krumpaszky HG, Ludtke R, Mickler A, Klauss V, Selbmann HK. Blindness incidence in Germany. A population-based study from Wurttemberg-Hohenzollern. Ophthalmologica 1999; 213: 176-82.
3. Kocur I, Resnikoff S. Visual impairment and blindness in Europe and their prevention. Br J Ophthalmol 2002; 86: 716-22.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
5. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-50.
6. Robison WG, Jr., Nagata M, Tillis TN, Laver N, Kinoshita JH. Aldose reductase and pericyte-endothelial cell contacts in retina and optic nerve. Invest Ophthalmol Vis Sci 1989; 30: 2293-9.
7. Hotta N, Nakamura J, Sakakibara F, et al. Electroretinogram in sucrose-fed diabetic rats treated with an aldose reductase inhibitor or an anticoagulant. Am J Physiol 1997; 273: E965-971.
8. Miwa K, Nakamura J, Hamada Y, et al. The role of polyol pathway in glucose-induced apoptosis of cultured retinal pericytes. Diabetes Res Clin Pract 2003; 60: 1-9.
9. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53: 2404-11.
10. Lee TS, MacGregor LC, Fluharty SJ, King GL. Differential regulation of protein kinase C and (Na,K)-adenosine triphosphatase activities by elevated glucose levels in retinal capillary endothelial cells. J Clin Invest 1989; 83: 90-4.
11. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997; 46: 1473-80.
12. Nakamura J, Kato K, Hamada Y, et al. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-5.
13. Hammes HP, Brownlee M, Lin J, Schleicher E, Bretzel RG. Diabetic retinopathy risk correlates with intracellular concentrations of the glycoxidation product Nepsilon-(carboxymethyl) lysine independently of glycohaemoglobin concentrations. Diabetologia 1999; 42: 603-7.
14. Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol 2002; 47 (suppl 2): S263-9.
15. Kuroki M, Voest EE, Amano S, et al. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 1996; 98: 1667-75.
16. Altomare E, Grattagliano I, Vendemaile G, Micelli-Ferrari T, Signorile A, Cardia L. Oxidative protein damage in human diabetic eye: evidence of a retinal participation. Eur J Clin Invest 1997; 27: 141-7.
17. Murata T, Nagai R, Ishibashi T, Inomuta H, Ikeda K, Horiuchi S. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia 1997; 40: 764-9.
18. Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia 1999; 42: 728-36.
19. Hammes HP, Wellensiek B, Kloting I, Sickel E, Bretzel RG, Brownlee M. The relationship of glycaemic level to advanced glycation end-product (AGE) accumulation and retinal pathology in the spontaneous diabetic hamster. Diabetologia 1998; 41: 165-70.
20. Robison WG, Jr., Nagata M, Laver N, Hohman TC, Kinoshita JH. Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Vis Sci 1989; 30: 2285-92.
21. Nonaka A, Kiryu J, Tsujikawa A, et al. PKC-beta inhibitor (LY333531) attenuates leukocyte entrapment in retinal microcirculation of diabetic rats. Invest Ophthalmol Vis Sci 2000; 41: 2702-6.
22. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005; 54: 2188-97.
23. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest Ophthalmol Vis Sci 2006; 47: 86-92.
24. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci U S A 1991; 88: 11555-8.
25. Hammes HP, Strodter D, Weiss A, Bretzel RG, Federlin K, Brownlee M. Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model. Diabetologia 1995; 38: 656-60.
26. Shinohara M, Masuyama T, Shoda T, et al. A new spontaneously diabetic non-obese Torii rat strain with severe ocular complications. Int J Exp Diabetes Res 2000; 1: 89-100.
27. Kakehashi A, Saito Y, Mori K, et al. Characteristics of diabetic retinopathy in SDT Rats. Diabetes Metab Res Rev 2006; 22: 455-61.
28. Boehm BO, Schilling S, Rosinger S, et al. Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema. Diabetologia 2004; 47: 1376-79.
29. Hirata K, Kubo K. Relationship between blood levels of N-carboxymethyl-lysine and pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 2004; 51: 537-44.
30. Sugiyama S, Miyata T, Horie K, et al. Advanced glycation end-products in diabetic nephropathy. Nephrol Dial Transplant 1996; 11 (suppl 5): 91-4.
31. Weiss MF, Rodby RA, Justice AC, Hricik DE. Free pentosidine and neopterin as markers of progression rate in diabetic nephropathy. Collaborative Study Group. Kidney Int 1998; 54: 193-202.
32. Capeans Tome C, De Rojas Silva MV, Rodriguez-Garcia J, Rodriguez-Segade S, Sanchez-Salorio M. Levels of pentosidine in the vitreous of eyes with proliferative diabetic retinopathy, proliferative vitreoretinopathy and retinal detachment. Graefes Arch Clin Exp Ophthalmol 2005; 243: 1272-6.